Butrym Aleksandra, Rybka Justyna, Baczyńska Dagmara, Poręba Rafał, Mazur Grzegorz, Kuliczkowski Kazimierz
Department of Haematology, Blood Neoplasms and Bone Marrow Transplantation, Wroclaw Medical University, Wroclaw 50-367, Poland; Department of Physiology, Wroclaw Medical University, Wroclaw 50-367, Poland.
Department of Haematology, Blood Neoplasms and Bone Marrow Transplantation, Wroclaw Medical University, Wroclaw 50-367, Poland.
Oncol Lett. 2016 Oct;12(4):2296-2300. doi: 10.3892/ol.2016.4970. Epub 2016 Aug 8.
MicroRNAs (miRs) are small non-coding RNAs that play important roles in cell differentiation and survival. Abnormal expression of miRs has been demonstrated in numerous types of cancer, including acute myeloid leukaemia (AML). The aim of the present study was to evaluate miR-181 expression at diagnosis and following the completion of chemotherapy in AML patients, with regard to clinical response and outcome, particularly in patients treated with azacitidine. miR-181 expression was analysed using reverse transcription-quantitative polymerase chain reaction in 95 bone marrow specimens from newly diagnosed AML patients and in 20 healthy subjects for comparison. The results revealed upregulated miR-181 expression in the total cohort of AML patients, which was correlated with longer survival. However, in a subset of older AML patients treated with azacitidine, low miR-181 expression at diagnosis was a predictor for complete remission and prolonged survival. The findings indicated that miR-181 has an important role in AML and determines response to azacitidine treatment in older AML patients.
微小RNA（miR）是一类小的非编码RNA，在细胞分化和存活中发挥重要作用。miR的异常表达已在包括急性髓系白血病（AML）在内的多种癌症类型中得到证实。本研究的目的是评估AML患者诊断时及化疗结束后的miR-181表达情况，以及其与临床反应和预后的关系，特别是接受阿扎胞苷治疗的患者。采用逆转录-定量聚合酶链反应分析了95例新诊断AML患者的骨髓标本及20例健康对照者的miR-181表达情况，以作比较。结果显示，AML患者总体队列中miR-181表达上调，且与较长生存期相关。然而，在接受阿扎胞苷治疗的老年AML患者亚组中，诊断时miR-181低表达是完全缓解和生存期延长的预测指标。这些发现表明，miR-181在AML中起重要作用，并决定老年AML患者对阿扎胞苷治疗的反应。
